Kite announces results from three-year analysis of ZUMA-12

Kite, a Gilead Company, announced results from a three-year follow-up analysis of ZUMA-12, a Phase 2 study of Yescarta as first-line treatment after two cycles of chemoimmunotherapy in patients with high-risk, large b-cell lymphoma. The analysis, which demonstrated durability of clinical benefit – both high complete response and objective response rates, including in patients with MYC and BCL2 and/or BCL6 rearrangements – was presented during an oral presentation at the 65th American Society of Hematology Annual Meeting & Exposition. “Patients with high-risk, large B-cell lymphoma, have a poor prognosis with currently available therapies,” said Julio C. Chavez, MD, lead investigator, Moffitt Cancer Center. “This is particularly true of patients with double- or triple-hit histology, who have a median survival of under a year with standard treatment. The impressive results at a median follow-up of 40 months build on the ZUMA-12 primary analysis, the first prospective Phase 2 study to evaluate CAR T-cell therapy as first-line treatment and reinforce axi-cel’s potential to be used safely and effectively in this patient population with high medical need.”